How long should we treat community-acquired pneumonia?

@article{Scalera2007HowLS,
  title={How long should we treat community-acquired pneumonia?},
  author={Nikole M. Scalera and Thomas M. Jr File},
  journal={Current Opinion in Infectious Diseases},
  year={2007},
  volume={20},
  pages={177–181}
}
  • N. ScaleraT. File
  • Published 1 April 2007
  • Medicine, Biology
  • Current Opinion in Infectious Diseases
Purpose of review The studies reviewed in this article suggest that a shorter duration of antibiotic therapy is comparable to standard therapy in the treatment of community-acquired pneumonia and promotes reduction of adverse events, microbial resistance, cost, and improved patient compliance. Recent findings Community-acquired pneumonia has traditionally been treated with a 7–14-day course of antimicrobial therapy. Since there have been few well controlled trials regarding the optimal duration… 

Evaluating Duration of Antimicrobial Therapy for Community-Acquired Pneumonia in Clinically Stable Patients

The majority of patients treated for CAP received durations of therapy exceeding national guideline recommendations resulting in a total of 645 excess days of antimicrobials, revealing potential opportunities for antimicrobial stewardship and provider education regarding duration of therapy for CAP.

Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis

No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy.

Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia

New recommendations from the Infectious Diseases Society of America and the American Thoracic Society suggest the use of “correct-spectrum” coverage, thereby reducing development of antimicrobial resistance and maintaining efficacy for newer classes of drugs in patients with moderate/severe CAP.

Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis

It is demonstrated that oral amoxicillin is a cost-effective treatment for the majority of children admitted to hospital with pneumonia, and thus determining which treatment is cost minimising is demonstrated.

Management and Prevention Strategies for Community-Acquired Pneumonia in the Gulf Corporation Council

Risk factors identify likelihood and severity of community-acquired pneumonia (CAP) and may allow prognostication and preventive strategies for CAP include the administration of pneumococcal and influenza vaccine in selected populations at risk.

Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: Insights into the ProHOSP study

The main effect in pneumonia was a severity- and bacteremia-adapted reduction of the duration of antibiotic courses, and PCT guidance had a differential effect on antibiotic exposure depending on the underlying type and severity of respiratory tract infection.

Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management

Antimicrobial selection for methicillin-resistant S. aureus infections with reduced susceptibility to vancomycin should be governed by disease severity, susceptibility patterns, knowledge of the limitations of current susceptibility testing, and strengths and weaknesses of the agents being considered.

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

In patients with LRTIs, a strategy of PCT guidance compared with standard guidelines resulted in similar rates of adverse outcomes, as well as lower rates of antibiotic exposure and antibiotic-associated adverse effects.

Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association

This updated CAP guideline covers comprehensive topics, including aetiology, antimicrobial resistance profile, diagnosis, empirical and targeted treatments, adjunctive and supportive therapies, as well as prophylaxis, and may help clinicians manage CAP patients more effectively and efficiently.

Pharmacoeconomic Analysis of Drugs Used in the Treatment of Pneumonia in Paediatric Population in a Tertiary Care Hospital in India—A Cost-of-Illness Study

The direct and indirect costs of diagnosis and medical treatment of paediatric patients with community acquired pneumonia who are hospitalized in a tertiary care hospital in India are assessed to assess the cost of antibiotic therapy for the treatment of pneumonia.

References

SHOWING 1-10 OF 42 REFERENCES

Short-Course Antimicrobial Therapy for Community-Acquired Pneumonia

Conclusions are drawn that remaining questions regarding the influence of patient selection, disease severity or choice of antimicrobial for short-course therapy indicate the need for further randomized controlled clinical trials in this area of research.

Value of short-course antimicrobial therapy in community-acquired pneumonia.

  • F. BlasiP. Tarsia
  • Medicine, Biology
    International journal of antimicrobial agents
  • 2005

Short-duration therapy for respiratory tract infections.

  • D. Goff
  • Medicine, Biology
    The Annals of pharmacotherapy
  • 2004
Short-course therapy for CARTIs (such as acute bacterial maxillary sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia) has been demonstrated to be effective with antibiotics from several different classes, including the ketolide antimicrobials.

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.

  • T. File
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
Available data suggest that with appropriate antibiotic selection, based on appropriate spectrum, potency, and pharmacokinetic/pharmacodynamic profile, lower respiratory tract infections in outpatients can be successfully treated in <7 days rather than the 7-14 days currently recommended.

What is the optimal duration of antibiotic therapy?

  • J. Paul
  • Medicine, Biology
    BMJ : British Medical Journal
  • 2006
Evidence in favour of a total of three days' treatment for uncomplicated cases of community acquired pneumonia is presented, suggesting that current guidelines recommending 7-10 days should be revised.

Short courses of antibiotic in acute otitis media and sinusitis infections.

  • M. Pichicero
  • Medicine
    The Journal of international medical research
  • 2000
Shortened-course therapy with agents such as cefuroxime axetil has the potential to improve patient compliance and so reduce the rate of clinical failure and the emergence of resistant strains.

Antimicrobial therapy of community-acquired pneumonia

Length of antibiotic therapy in in-patients with primary pneumonias.

It is suggested that in primary pneumonia it is more rational to stop antibiotics after the patient has been afebrile for 24 hours, which leads to a shorter stay in hospital and to the use of less antibiotic.